03 Sep Científica por amor al arte
El mío es un caso atípico. Mi nombre es Paula Fernández, soy Dra. en Bioquímica y Biología Molecular por la Universidad de Oviedo y empecé a dedicarme a la investigación por falta de oportunidades laborales....
Author: laminar
25 Aug Cabezonería 1 – Discapacidad física 0
Dentro de mis limitaciones siempre he sido afortunada bueno, mejor dicho, he luchado para serlo. Tengo 39 años, soy Doctora en Biología y tengo una enfermedad ósea de nacimiento que ha ocasionado que viva con una discapacidad física y movilidad reducida....
15 Aug La técnica de CRISPR en Laminar Pharma
La técnica CRISPR toma su nombre por sus siglas en inglés (Clustered Regularly Interspaced Short Palindromic Repeats). Es una herramienta que nos permite manipular la información genética contenida en las células, lo que se conoce como ‘ingeniería genética’....
03 Jun (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Massalha W, et al. Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity. Biosci Rep. 2019 Jan 18;39(1). pii: BSR20181661. doi: 10.1042/BSR20181661[/vc_column_text][vc_separator type="transparent" up="35"][/vc_column][vc_column width="1/6"][/vc_column][/vc_row]...
29 May Laminar Pharma announces IND approval by the FDA to proceed with a PhI paediatric trial assessing 2OHOA in children with advanced brain and other solid tumours
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Following the positive conclusion of a PI/IIa trial in Europe with 2OHOA in adult patients with advanced solid tumours, including malignant glioma, this paediatric trial will investigate the safety profile and preliminary anticancer...
22 Jan Laminar Pharma awarded a 6,15M€ grant by the H2020 Programme to conduct a PIIb trial with 2OHOA in patients with newly-diagnosed glioblastoma
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Laminar Pharma and integrated by 12 leading clinical research institutions, Universities and SMEs...
05 Jun Final results of the MIN-001-1203 study with 2OHOA in oncology presented at ASCO 2017 annual meeting in Chicago
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]54 patients with advanced solid tumours have participated in the Phase I/IIa clinical study with 2OHOA, half of them with malignant glioma. Primary objective has been achieved, with the definition or the MTD,...
12 Dec Dr Rosselló awarded a Felip Bauçà grant
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca (Spain), December 12th 2016 – The postdoctoral researcher Catalina Ana Rosselló Castillo has been awarded a Felip Bauçà fellowship at the CAIB (Comunitat Autònoma de les Illes Balears) Postdoctoral call from the...
01 Aug Laminar Pharma closes patient recruitment in its first clinical study with 2OHOA in cancer
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma announces the closure of patient recruitment in its first clinical study with 2OHOA (MIN-001-1203), a Phase I/IIa open label, non-randomized, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy study of 2OHOA in adult...
23 Nov Laminar Pharma initiates recruitment in expansion cohorts of clinical study with 2OHOA in cancer
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Palma de Mallorca (Spain), November 23rd 2015 – Laminar Pharma announced today that in the Dose Escalation TC held this morning with all the Clinical Investigators and the Medical Monitor of the MIN-001-1203 study...